Von den Profis lernen. Beim Kostensieger handeln.

Eröffne jetzt dein Depot bei unserem Broker finanzen.net ZERO – und lies 3 Monate kostenfrei das Fachmagazin der Börsenexperten, die NVIDIA schon vor einem Jahrzehnt auf der Kaufliste hatten.

Handle deine Aktien beim Kostensieger der Stiftung Warentest (12/2025)

Entdecke mit dem aktien-Magazin chancenreiche Titel, bevor der Mainstream sie kennt (Wert: 147 €)

Sichere dir zusätzlich 50 € Neukundenbonus direkt auf dein Cash-Konto

Insmed Aktie

95,34 EUR -0,29 EUR -0,30 %

13:32:25

STU

109,51 USD -6,05 USD -5,24 %

vorbörslich13:11:23

BTT

Insmed jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.22,00 Mrd. EUR

Div. Rendite0,00%

WKNA1JJA3

ISINUS4576693075

SymbolINSM

Insmed Aktien News

Sortieren:Datum Meistgelesen

09.01.26PR NewswireInsmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference

08.01.26PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM

02.01.26PR NewswireInsmed To Present at the 44th Annual J.P. Morgan Healthcare Conference

WerbungInsmed-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

01.01.26PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM

17.12.25PR NewswireInsmed Provides Clinical and Business Update

04.12.25PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

18.11.25PR NewswireEuropean Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

18.11.25PR NewswireEuropean Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union

13.11.25PR NewswireInsmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good

05.11.25PR NewswireInsmed To Present at November and December 2025 Investor Conferences

30.10.25PR NewswireInsmed Reports Third-Quarter 2025 Financial Results and Provides Business Update

23.10.25PR NewswireInsmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List

17.10.25PR NewswireCHMP Recommends EU Approval of BRINSUPRI™ (brensocatib) for the Treatment of Non-Cystic Fibrosis Bronchiectasis

16.10.25PR NewswireInsmed to Present Multiple Analyses from Phase 3 ASPEN Study at the American College of Chest Physicians Annual Meeting 2025

15.10.25PR NewswireInsmed to Host Third-Quarter 2025 Financial Results Conference Call on Thursday, October 30, 2025

22.09.25PR NewswireInsmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025

05.09.25PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

27.08.25PR NewswireBloomberg 500 (B500) Index Adds Sixteen Securities Following Semi-Annual Reconstitution

21.08.25PR NewswireInsmed To Present at September Investor Conferences

12.08.25PR NewswireFDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

07.08.25PR NewswireInsmed Reports Second-Quarter 2025 Financial Results and Provides Business Update

24.07.25PR NewswireInsmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025

10.06.25PR NewswireInsmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

04.06.25PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

28.05.25PR NewswireInsmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference

21.05.25PR NewswireBrensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study

08.05.25PR NewswireInsmed Reports First-Quarter 2025 Financial Results and Provides Business Update

29.04.25PR NewswireInsmed To Present at the BofA Securities 2025 Health Care Conference

23.04.25PR NewswireNew England Journal of Medicine Publishes Positive Results from Insmed's Pivotal Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

23.04.25PR NewswireInsmed to Host First-Quarter 2025 Financial Results Conference Call on Thursday, May 8, 2025

25.03.25PR NewswireInsmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference

10.03.25PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

24.02.25PR NewswireInsmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis

20.02.25PR NewswireInsmed Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides Business Update

11.02.25PR NewswireInsmed To Present at March 2025 Investor Conferences

10.02.25PR NewswireInsmed to Host Fourth-Quarter and Full-Year 2024 Financial Results Conference Call on Thursday, February 20, 2025

07.02.25PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

06.02.25PR NewswireFDA Grants Priority Review to Insmed's Brensocatib for Treatment of Bronchiectasis with PDUFA Target Action Date Set for August 12, 2025

10.01.25PR NewswireInsmed Provides Business Update at 43rd Annual J.P. Morgan Healthcare Conference

03.01.25PR NewswireInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed News

Insmed News: auf dieser Seite finden Sie alle Insmed News und Nachrichten zur Insmed Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Insmed News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Insmed News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.